Rare Sugar Allulose Induces Apolipoprotein A1 Gene Expression

Allulose Is Not Just a Sweetener

If you formulate with allulose, you probably track sweetness, solubility, and clean label appeal. A new cell-based study gives you another reason to keep an eye on this rare sugar. Allulose can switch on the gene for apolipoprotein A-I (apo A-I), the main protein in HDL particles.

Background

The work comes from the Journal of the Endocrine Society (DOI: 10.1210/jendso/bvaa046). It was presented as MON-711. Apo A-I is the structural core of high-density lipoprotein, better known as HDL. Raising apo A-I production is a logical way to support HDL formation. Most ingredients do not even enter that conversation. This study puts allulose in it.

What the Study Did

The researchers worked with HepG2 cells, a standard human liver cell line. They gave the cells allulose and then measured two things: apo A-I protein secreted into the culture medium, and apo A-I mRNA inside the cells. They also examined the apo A-I gene promoter to find which DNA elements matter.

Key Findings

Allulose increased both apo A-I protein and mRNA in a dose-dependent way. The rise was more than two-fold. That is a solid signal in a cell model. The effect required a specific promoter element called the insulin response core element (IRCE) and the transcription factor SP1. That gives the finding a clear molecular handle. The authors see this as a potential anti-atherosclerotic mechanism, likely through higher HDL levels.

What the study measured	What the researchers observed
Apo A-I protein secretion	Increased with allulose dose, >2-fold
Apo A-I mRNA	Increased with allulose dose, >2-fold
Apo A-I gene promoter	Needed IRCE and SP1 for the response
Putative outcome	More apo A-I available for HDL, possible anti-atherosclerotic effect

What It Means for Formulators

You cannot put “raises HDL” on a label yet. The data come from cultured liver cells, not from humans. But you can use the finding internally, in white papers, and in supplier conversations.

This also adds a metabolic dimension to allulose. Formulators already use allulose for bulk, browning, and glycemic response. Now there is a mechanism story tied to lipid biology. The involvement of an insulin response element is especially interesting. It connects the same sweetener to a known regulatory pathway in liver cells.

For ingredient buyers, this paper is a useful benchmark. Ask suppliers if their allulose documentation includes peer-reviewed mechanistic research. This study is not the final word, but it shows that allulose can act directly on a gene involved in HDL metabolism.

Frequently Asked Questions

Q: Does this prove allulose raises HDL in people? A: No. It is a cell study. Human trials still need to confirm whether dietary allulose changes apo A-I or HDL levels in the body.

Q: What is apo A-I? A: Apo A-I is the main apolipoprotein in HDL. The body needs it to assemble HDL particles and move cholesterol around.

Q: Which genetic element does allulose target? A: The insulin response core element (IRCE) in the apo A-I gene promoter, together with transcription factor SP1.

Allulose keeps showing up in places sugar replacements never go. A two-fold, dose-dependent increase in apo A-I messenger RNA and protein is not a small effect. The IRCE/SP1 mechanism gives researchers a clear path to follow. For now, treat it as a promising lead. Formulators and buyers should watch for animal data and clinical follow-up. If those studies hold up, allulose may earn a new role beyond sweetness. That would change how the industry talks about rare sugars.